Clinical Trial Update: A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating treat-to-target strategy and dosing flexibility of oral upadacitinib in adults with moderate-to-severe atopic dermatitis. Results hav…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• RINVOQ (Upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Atopic Dermatitis | Phase 4 | Status: COMPLETED | Results posted: 2025-07-29